Keros Therapeutics Inc risk profile
9 Contained slack in every measured input
Measured 21 October 2026 from KROS's filed statements. Recomputed nightly.
9 (Contained), driven by Market expectation at 73, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 73 | Stretched | Volatile | Drawdown from the 52-week high — 49.4% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -6,792.6 percentage points |
| Cash conversion | 22 | Normal | Easing | Cash conversion — 1.24x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -3.92x |
| Competitive position | 0 | Contained | Stable | R&D-intensity gap against peers — +24.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Keros Therapeutics Inc